New combo therapy shows promise for untreatable liver cancer
NCT ID NCT07204327
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well a combination of two drugs (atezolizumab and bevacizumab) plus local treatments like chemo or radiation works for people with advanced liver cancer that can't be removed by surgery. About 1,136 patients from hospitals in China and Asia will be included. The goal is to see if this approach helps people live longer and controls the cancer better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, 210009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- AI takes on liver cancer: could a computer help pick the right immunotherapy?
- Immunotherapy combo tested against untreatable liver cancer
- Liver cancer drug combo shows promise in large trial
- New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo
- New radioactive beads aim to outperform standard liver cancer therapy